FDA is investigating fraudulent schemes trafficking counterfeit semaglutide (Ozempic); Moderna plans to begin a late-stage trial of its combined COVID-19 and flu vaccine later this year; CMS will begin restricting predictive software used by insurance companies next year.
The FDA is currently investigating several fraudulent schemes appearing to traffic counterfeit versions of semaglutide (Ozempic), according to CBS News. According to an alert sent to Pharmaceutical Cargo Security Coalition industry members, FDA investigators found that fraudsters are acting as medical wholesale employees and effectively taking over accounts of legitimate licensed companies. Then, amid the demand surge, the fraudsters target unsuspecting pharmacies looking for discounts on the drug. The pharmacies that fell victim reportedly either received counterfeit semaglutide pens, versions diverted from other countries, or none. This comes after the discovery earlier this year that a counterfeit semaglutide injector pen was being sold at a US pharmacy.
Moderna announced Wednesday that it plans to begin a phase 3 trial later this year in adults 50 years and older for a combination COVID-19–flu vaccine, according to Axios. The company noted that, in preliminary trials, the mRNA-1083 combination vaccine yielded antibody levels in the blood similar to or greater than a standard dose flu vaccine and COVID-19 vaccine. Also, in comparison to the standalone vaccines, Moderna did not identify any new safety concerns in the preliminary trials of the combination vaccine. Moderna’s COVID-flu vaccine comes after Pfizer and BioNTech launched a trial of their combination vaccine late last year, and Novavax also has an investigational shot. The company looks toward regulatory approval in 2025.
Next year, CMS will begin restricting how insurance companies use predictive technology tools to make coverage decisions for patients with Medicare Advantage plans, according to KFF Health News. For example, naviHealth’s “nH Predict” tool sifts through millions of medical records to match those with similar diagnoses and characteristics; its algorithm then uses these details to anticipate what kind of care a specific patient will need and for how long. Despite the patient needing further treatment, the tool often predicts a patient’s discharge date, which reportedly often coincides with when the insurer cuts off coverage. Beginning in January, new federal rules will help mitigate algorithm use in coverage decisions. These rules require insurance companies to ensure they are making decisions based on the specific individual’s circumstances instead of an algorithm or software that does not account for them.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Traditional Medicare Supplemental Insurance and the Rise of Medicare Advantage
May 7th 2024Rising Medicare Advantage enrollment occurred alongside declines in enrollment in traditional Medicare with employer-sponsored supplemental coverage and traditional Medicare without supplemental coverage.
Read More
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More